| Literature DB >> 33380707 |
Karishma R Kulkarni1, R P S Shyam1, Virupakshappa Irappa Bagewadi1, Guru S Gowda1, B R Manjunatha2, Harihara N Shashidhara1, Vinay Basavaraju1, Narayana Manjunatha2, Sydney Moirangthem1, Channaveerachari Naveen Kumar2, Suresh Bada Math2.
Abstract
BACKGROUND &Entities:
Keywords: India; psychiatric service; rehabilitation; telepsychiatry; Collaborative care
Mesh:
Year: 2020 PMID: 33380707 PMCID: PMC8061593 DOI: 10.4103/ijmr.IJMR_676_18
Source DB: PubMed Journal: Indian J Med Res ISSN: 0971-5916 Impact factor: 2.375
Sociodemographic and clinical characteristics of patients (n=132)
| Age at assessment (yr), mean±SD | 43.8±12.1 |
| Gender, n (%) | |
| Male | 99 (75) |
| Female | 33 (25) |
| Teleconsultations, mean±SD | |
| Mean number of consultations per patient | 7.8±4.9 |
| Mean duration between consecutive consultations | 2.1±1 |
| Diagnosis at initial consultation, n (%) | |
| Psychosis | 63 (47.7) |
| Schizophrenia | 40 (30.3) |
| Mental retardation+psychosis | 16 (12.1) |
| Depression+psychosis | 5 (3.8) |
| Bipolar disorder | 5 (3.8) |
| Mental retardation | 3 (2.3) |
| IQ testing | |
| IQ advised | 32 |
| IQ performed | 23 |
| Dull normal | 1/23 |
| Mild | 7/23 |
| Moderate | 13/23 |
| Severe | 2/23 |
| Comorbid medical illness, n (%) | |
| Hypertension | 1 (0.7) |
| Diabetes | 3 (2.1) |
| Seizure disorder | 6 (4.3) |
| Substance use disorder | 8 (5.8) |
| Dementia | 3 (2.1) |
IQ, intelligence quotient; SD, standard deviation
Psychiatric diagnostic revisions
| Baseline diagnosis | Revised diagnosis | n (%) |
|---|---|---|
| Psychosis | Dementia | 1 (0.7) |
| Schizophrenia | Obsessive-compulsive disorder | 1 (0.7) |
| Psychosis/schizophrenia | Mental retardation | 2 (1.5) |
| Psychosis | Mental retardation + psychosis | 9 (6.9) |
| Total diagnostic revision | 13 (9.8) |
Clinical outcome and treatment response characteristics of patients (n=132)
| Variable | n (%) |
|---|---|
| Initial treatment (with collaborative care) | |
| Antipsychotic medication | 111 (84.1) |
| Mood stabilizer | 4 (3) |
| Antipsychotic medication+mood stabilizer | 11 (8.3) |
| Antipsychotic medication+anti-depressant medication | 6 (4.4) |
| Treatment revised | 39 (29.5) |
| Antipsychotic medication (first trial) | |
| Tablet risperidone | 78 (59.1) |
| Tablet olanzapine | 38 (28.8) |
| Others | 5 (3.5) |
| Antipsychotic medication prescribed in combination with | |
| Injection fluphenazine | 20 (15.1) |
| Tablet valproate | 17 (12.8) |
| Antipsychotic medication (next trial) | |
| Tablet clozapine | 24 (18.1) |
| Tablet olanzapine | 12 (9.1) |
| Chlorpromazine equivalents (mg), mean±SD | 341±163 |
| Clinical outcome (based on clinician experience) | |
| <50 per cent (poor) | 36 (27.3) |
| 50-75 per cent (partial) | 54 (40.9) |
| >75 per cent (good) | 26 (19.7) |
| Adverse side effects | |
| Extrapyramidal symptoms/syndromes | 7 (5.3) |
| Others | 3 (2.3) |
| Referral for intensive psychiatric care at higher centre | 4 (3) |